日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Molecular Profiling for Precision Oncology: Moving Beyond Feasibility and Safety

分子谱分析在精准肿瘤学中的应用:超越可行性和安全性

Freidlin, Boris; Korn, Edward L; Maki, Robert G

Highly Water-Soluble Microneedle Patch for Short Wear Time and Rapid Drug Delivery

高水溶性微针贴片,佩戴时间短,给药速度快

Wood-Yang, Amy J; Sankaranarayanan, Abishek; Freidlin, Max J; Prausnitz, Mark R

Effects of location of primary tumor on survival after pulmonary metastasectomy for colorectal cancer

原发肿瘤位置对结直肠癌肺转移瘤切除术后生存率的影响

Putatunda, Vijay; Hernandez, Frank Villa; Freidlin, Max J; Hoang, Chuong D; Hernandez, Jonathan M; Carr, Shamus R

Evaluating the impact of stratification on the power and cross-arm balance of randomized phase 2 clinical trials

评估分层对随机 II 期临床试验的效力和交叉组平衡的影响

Moseley, Anna; LeBlanc, Michael; Freidlin, Boris; Shallis, Rory M; Zeidan, Amer M; Sallman, David A; Erba, Harry P; Little, Richard F; Othus, Megan

Avoiding Delays in Reporting Time-to-Event Randomized Trials: Calendar Backstops and Other Approaches

避免报告生存时间随机试验结果的延迟:日历后备措施和其他方法

Othus, Megan; Freidlin, Boris; Korn, Edward L

Efficiency of Biomarker-Driven Clinical Trial Designs

生物标志物驱动的临床试验设计的效率

Freidlin, Boris; Korn, Edward L

Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN)

利用贝叶斯最优区间设计(BOIN)在I期剂量递增试验中回填患者

Zhao, Yixuan; Yuan, Ying; Korn, Edward L; Freidlin, Boris

Two-to-One Randomization: Rarely Advisable

二比一随机化:极少推荐

Freidlin, Boris; Korn, Edward L

Accrual Suspensions in Seamless Phase II/III Trials: A Review of NRG Oncology Trials

无缝二/三期临床试验中的受试者招募暂停:NRG肿瘤试验回顾

Hu, Chen; Freidlin, Boris; Korn, Edward L

Timing and Reporting of Secondary Overall Survival End Points for Phase III Trials in Advanced/Metastatic Disease

晚期/转移性疾病 III 期试验中次要总生存期终点的时机和报告

Freidlin, Boris; Korde, Larissa A; Korn, Edward L